Glis3是甲状腺原基特化的关键调控因子
本研究利用斑马鱼模型探讨Glis3在甲状腺器官发生中的作用。glis3敲低胚胎甲状腺原基中nkx2.4和pax2a表达降低,分化甲状腺组织缩小、tg和slc5a5表达下降、T4阳性滤泡减少,伴tshba升高,并显示Glis3是SHH通路效应因子。
要点
- glis3敲低斑马鱼胚胎甲状腺原基中nkx2.4和pax2a表达降低。
- glis3敲低胚胎分化甲状腺组织缩小、tg和slc5a5表达下降、T4阳性滤泡减少,伴tshba升高。
- Glis3是SHH通路效应因子,SHH通路抑制可重现glis3敲低胚胎的甲状腺缺陷。
核心结论
- glis3在SHH通路内似乎决定定向于甲状腺命运的内胚层细胞数量。
- 这是Glis3参与甲状腺发育不良的首个证据,扩展了对甲状腺发育和先天性甲状腺功能减退遗传基础的理解。
研究设计与样本
- 研究利用斑马鱼模型,在1至2细胞期显微注射特异性glis3 morpholino生成瞬时glis3敲低胚胎(glis3 morphants),以在体内分析甲状腺表型。
- 研究进行了原位杂交、免疫组化和药理学处理等额外分析以进一步分子表征。
主要发现
- glis3 morphants在甲状腺原基水平显示早期转录因子nkx2.4和pax2a表达降低,且该降低不是由咽内胚层增殖或凋亡改变引起。
- glis3 morphants中分化甲状腺组织缩小,tg和slc5a5表达下降,产甲状腺素(T4)滤泡数量少,并伴有tshba(人TSHβ的同源物)升高。
- glis3 morphants有胰腺β细胞缺陷,但无肝脏缺陷。
- 体外和体内数据表明Glis3是Sonic Hedgehog(SHH)通路的效应因子。
- 分子和药理学抑制SHH可重现glis3 morphant中观察到的甲状腺缺陷。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: GLIS3 (GLI-Similar protein 3) is a transcription factor involved in several cellular processes. Homozygous mutations in the GLIS3 gene have been typically associated with neonatal diabetes and congenital hypothyroidism (CH) in a syndrome called NDH. NDH patients present developmental abnormalities including endocrine pancreas defects and a spectrum of thyroid abnormalities, mainly including thyroid dysgenesis (TD). The mouse models revealed a key role of Glis3 in pancreatic islets but not in early thyroid development, as Glis3 was described to retain a role in regulating thyroid hormone synthesis downstream the thyrotropin (TSH)/TSHR signaling pathway and in postnatal follicle proliferation. Hence, in this study, we have been taking advantage of the zebrafish model to gain insights on the Glis3 activity during thyroid organogenesis. Methods: Transient glis3-knockdown zebrafish embryos (called glis3 morphants) were generated by the microinjection of specific glis3 morpholinos at one- to two-cell stage to analyze the thyroid phenotype in vivo. Several additional analyses (in situ hybridization, immunohistochemistry, and pharmacological treatments) were performed for further molecular characterization. Results: The analysis of thyroid embryonic development revealed that Glis3 is involved in early steps of thyroid specification. glis3 morphants exhibited a reduced expression of the early transcription factors nkx2.4 and pax2a at the thyroid primordium level, which is not caused by changes in proliferation or apoptosis of the pharyngeal endoderm. As a result, the differentiated thyroid tissue in morphants appeared reduced in size with decreased expression of tg and slc5a5, a low number of thyroxine (T4)-producing follicles, associated with an elevation of tshba (homologous of the human TSHβ), thus resembling the clinical and biochemical manifestations of patients with TD. Interestingly, glis3 morphants have pancreatic β-cell defects, but not liver defects. In vitro and in vivo data also demonstrated that Glis3 is an effector of the Sonic Hedgehog (SHH) pathway. Molecular and pharmacological inhibition of SHH reproduced the thyroid defects observed in glis3 morphant. Conclusions: Our results demonstrate that glis3, within the SHH pathway, appears to determine the number of endodermal cells committed to a thyroid fate. This is the first evidence of the involvement of Glis3 in TD, thereby expanding the understanding of the genetic basis of thyroid development and CH.
引用
- Rurale G, Marelli F, Duminuco P, et al. Glis3 as a Critical Regulator of Thyroid Primordium Specification. Thyroid. 2020. PMID: 31797737. doi:10.1089/thy.2019.0196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。